At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell lung cancer (NSCLC) significantly affects patient outcomes. This study, presented by Dr. Yongchang Zhang from Hunan Cancer Hospital, showed that infusions administered before 3 PM led to better progression-free survival (PFS) and overall survival (OS) … Continue reading Timing of Immunotherapy NSCLC: Survival Gains at ASCO 2025